• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Tabula Rasa HealthCare Inc. (Amendment)

    6/21/22 11:37:28 AM ET
    $TRHC
    Business Services
    Consumer Discretionary
    Get the next $TRHC alert in real time by email
    SC 13D/A 1 d717933dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    TABULA RASA HEALTHCARE, INC.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    873379101

    (CUSIP Number)

    David Maryles

    Managing Director, Legal and Compliance

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

    (212) 810-5300

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    June 18, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box:  ☒

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.: 873379101

     

      1    

      NAMES OF REPORTING PERSONS

     

      BlackRock, Inc.

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS

     

      OO

      5  

      CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2 (d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7     

      SOLE VOTING POWER

     

      1,483,290

         8   

      SHARED VOTING POWER

     

      0

         9   

      SOLE DISPOSITIVE POWER

     

      1,500,489

       10   

      SHARED DISPOSITIVE POWER

     

      0

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      1,500,489

    12  

      CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      5.8%

    14  

      TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

      HC

     

    2


    EXPLANATORY NOTE

    This Amendment No. 1 (this “Amendment No. 1”) amends and supplements the Schedule 13D (as amended, the “Schedule 13D”) filed with the U.S. Securities and Exchange Commission on April 21, 2022 (the “Original Schedule 13D”), by and on behalf of BlackRock, Inc. (“BlackRock”), relating to the common stock, par value $0.0001 per share (the “Common Stock”), of Tabula Rasa HealthCare, Inc., a Delaware corporation (the “Issuer”).

    Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Original Schedule 13D. Capitalized terms used but not otherwise defined in this Amendment No. 1 shall have the meanings ascribed to them in the Original Schedule 13D.

    Item 2. Identity and Background.

    The information set forth in amended and restated Annex A hereto is incorporated by reference in this amended Item 2.

    Item 4. Purpose of Transaction.

    Item 4 is hereby amended and supplemented to include the following:

    As previously disclosed in the Original Schedule 13D, a fund advised by an Advisory Subsidiary previously authorized one of its portfolio companies, identified in this Amendment No. 1 as Transaction Data Systems, Inc., a Florida corporation and one of the portfolio companies of such fund (“Bidder”), to participate in a process being conducted by the Issuer to divest certain assets of the Issuer. On June 18, 2022, Bidder, Issuer and Tabula Rasa HealthCare Group, Inc., a Delaware corporation and wholly-owned subsidiary of Issuer (“Seller”), entered into an Asset Purchase Agreement (the “Purchase Agreement”), pursuant to which Seller agreed to sell to Bidder its unincorporated PrescribeWellness business division (the “PrescribeWellness Business”) and the assets, properties, and rights that are primarily used or held for use in connection with the PrescribeWellness Business, in accordance with the terms and conditions set forth therein, for up to $140,000,000 in cash, of which $125,000,000 will be paid at closing subject to certain adjustments related to the net working capital of the PrescribeWellness Business (the “Base Purchase Price”). The additional $15,000,000 is contingent consideration that will be paid to Seller based upon the PrescribeWellness Business’s achievement of certain performance-based metrics during the fiscal years ending December 31, 2023 and 2024. The Purchase Agreement further provides for a post-closing, true-up adjustment based on the parties’ determination of the Final Working Capital Amount. Consummation of the transactions contemplated by the Purchase Agreement is subject to certain conditions and approvals, including without limitation (i) the consummation of Seller’s acquisition of certain intellectual property and related assets from karmadata, Inc., a Delaware corporation, and (ii) the satisfaction or waiver of certain customary closing conditions, including receipt of all required approvals under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

    The foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement filed as an exhibit to this Amendment No. 1, and incorporated herein by reference.

    The activities described herein will not restrict the Advisory Subsidiaries’ exercise of investment or voting power with respect to the Common Stock to which this Schedule 13D relates. Except as set forth in this Schedule 13D, BlackRock has no present plans or proposals that relate to or would result in any of the actions described in Item 4 (a) through (j) of this Schedule 13D. Each of the Advisory Subsidiaries may evaluate on a continuing basis its client accounts’ investment in the Issuer, and BlackRock expects that such Advisory Subsidiaries may from time to time acquire or dispose of Common Stock or other securities of the Issuer on behalf of such client accounts. Any acquisitions or dispositions will depend upon (i) the price and availability of the Issuer’s securities; (ii) subsequent developments concerning the Issuer’s business and prospects and the industry in which the Issuer operates; (iii) the Advisory Subsidiaries’ general investment policies with respect to the applicable accounts managed by the Advisory Subsidiaries; (iv) other investment and business opportunities available to the Advisory Subsidiaries on behalf of their clients; (v) general market and economic conditions; (vi) tax considerations; and (vii) such other factors as the Advisory Subsidiaries may consider relevant. Any such acquisitions or dispositions may be made, subject to applicable law, in open market transactions or privately negotiated transactions.

    Item 5. Interest in Securities of the Issuer.

    Item 5 (a) – (c) is hereby amended and restated as follows:

    (a) and (b) The responses of BlackRock to Rows (7) through (11), and (13) of the cover page of this Schedule 13D are incorporated herein by reference.

    The aggregate percentage of shares of Common Stock reported as beneficially owned by BlackRock was calculated based on 25,849,263 shares of Common Stock issued and outstanding as of April 30, 2022, as disclosed in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the U.S. Securities and Exchange Commission on May 9, 2022.

    The Common Stock beneficially owned by BlackRock includes Common Stock beneficially owned by the Advisory Subsidiaries, including BlackRock Advisors, LLC, Aperio Group, LLC, BlackRock (Netherlands) B.V., BlackRock Fund Advisors, BlackRock Institutional Trust Company, National Association, BlackRock Financial Management, Inc., BlackRock Investment Management, LLC, BlackRock Investment Management (UK) Limited, and BlackRock Asset Management Canada Limited, none of which individually beneficially owns in excess of 5% of the outstanding Common Stock.

    (c) Annex B, attached hereto, sets forth transactions in the Common Stock that were effected since the filing of the Original Schedule 13D. The transactions in the Common Stock described on Annex B were effected on securities exchanges unless otherwise indicated therein.

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Item 6 is hereby amended and supplemented to include the following:

    In addition, a BlackRock-managed fund is a party to a derivative agreement in the form of contract for difference (the “CFD”) in an aggregate notional principal amount of 7,742 shares of Common Stock of the Issuer. The CFD provides the BlackRock-managed fund with economic results that are comparable to the economic results of ownership but do not provide them with the power to vote or direct the voting or dispose of or direct the disposition of the shares that are referenced in the CFD (such shares, the “Subject Shares”). BlackRock disclaims beneficial ownership of the Subject Shares. The counterparty to the CFD is an unaffiliated third-party financial institution.

    Item 7. Material to be filed as Exhibits.

    Item 7 is hereby amended and supplemented to include the following:

     

    Exhibit 2    Asset Purchase Agreement dated as of June 18, 2022 (incorporated herein by reference to Exhibit 2.1 to the Issuer’s Current Report on Form 8-K filed on June 21, 2022).

     

    3


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: June 21, 2022     BLACKROCK, INC.
        By:  

    /s/ David Maryles

        Name:   David Maryles
        Title:   Attorney in Fact


    Annex A is hereby amended and restated as follows:

    Annex A

    The following is a list of the executive officers and directors of BlackRock, Inc. (collectively, the “Covered Persons”), setting forth the present principal occupation or employment and the name, principal business and address of any corporation or other organization in which such employment is conducted and citizenship for each such person. Each Covered Person is a citizen of the United States, unless otherwise noted, and does not have any other principal occupation (outside of similar positions held with respect to other entities directly or indirectly managed or advised by BlackRock).

    Executive Officers

     

    Name   

    Principal Occupation or Employment

      

    Business Address

      

    Citizenship

    Laurence D. Fink    Chairman and Chief Executive Officer   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    Robert S. Kapito    President   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    Rachel Lord    Senior Managing Director and Chair and Head of Asia Pacific   

    BlackRock, Inc.

    16/F Champion Tower

    3 Garden Road Central, Hong Kong

       U.K.
    Robert L. Goldstein    Senior Managing Director, Chief Operating Officer and Global Head of BlackRock Solutions   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    J. Richard Kushel    Senior Managing Director and Head of the Portfolio Management Group   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    Stephen Cohen    Senior Managing Director and Head of Europe, Middle East and Africa   

    BlackRock, Inc.

    Drapers Gardens

    12 Throgmorton Avenue

    London EC2N 2DL United Kingdom

       U.K.
    Mark S. McCombe    Senior Managing Director and Chief Client Officer   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.K.
    Christopher J. Meade    Senior Managing Director, Chief Legal Officer and General Counsel   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    Manish Mehta    Senior Managing Director and Global Head of Human Resources   

    BlackRock, Inc.

    400 Howard Street

    San Francisco, CA 94105

       U.S.
    Gary S. Shedlin    Senior Managing Director and Chief Financial Officer   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    Mark Wiedman    Senior Managing Director and Head of International and of Corporate Strategy   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.


    Directors

     

    Name   

    Principal Occupation or Employment

      

    Business Address

      

    Citizenship

    Bader M. Alsaad    Arab Fund for Economic & Social Development - Chairman of the Board and Director General   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       Kuwait
    Pamela Daley    General Electric Company - Former Senior Vice President of Corporate Business Development   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    Laurence D. Fink    BlackRock, Inc. - Chairman and Chief Executive Officer   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    Beth Ford   

    Land O’Lakes, Inc. - President and

    Chief Executive Officer

      

    Land O’Lakes, Inc.

    4001 Lexington Ave. North

    Arden Hills, MN 55126

       U.S.
    William E. Ford    General Atlantic - Chairman and Chief Executive Officer   

    General Atlantic

    Park Avenue Plaza

    55 East 52nd Street, 33rd Fl

    New York, NY 10055

       U.S.
    Fabrizio Freda    The Estée Lauder Companies Inc. - President and Chief Executive Officer   

    Estée Lauder Companies

    767 Fifth Avenue, 40th Fl

    New York, NY 10153

       Italy & U.S.
    Murry S. Gerber   

    EQT Corporation - Former Executive Chairman, Chairman,

    President and CEO

      

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    Margaret “Peggy” L. Johnson    Magic Leap, Inc. - Chief Executive Officer   

    Magic Leap

    7500 W. Sunrise Blvd

    Plantation, FL 33322

       U.S.
    Robert S. Kapito    BlackRock, Inc. - President   

    BlackRock, Inc.

    55 East 52nd Street

    New York, NY 10055

       U.S.
    Cheryl D. Mills    BlackIvy Group LLC - Founder and Chief Executive Officer   

    BlackIvy Group LLC

    2300 N Street NW

    Suite 630

    Washington DC 20037

       U.S.
    Gordon M. Nixon    Royal Bank of Canada - Former President, CEO and Board Member    BlackRock, Inc. 55 East 52nd Street New York, NY 10055    Canada
    Kristin C. Peck    Zoetis Inc. - Chief Executive Officer    Zoetis Inc. 10 Sylvan Way Parsippany, NJ 07054    U.S.
    Charles H. Robbins    Cisco Systems, Inc. - Chairman and Chief Executive Officer    Cisco Systems, Inc. 300 West Tasman Drive San Jose, CA 95134 7    U.S.
    Marco Antonio Slim Domit    Grupo Financiero Inbursa, S.A.B. de C.V. - Chairman    Grupo Financiero Inbursa Av. Paseo de las Palmas, #736 Floor 1 Colonia Lomas de Chapultepec C.P. 11000, México D.F.    Mexico
    Hans E. Vestberg   

    Verizon Communications Inc. -

    Chairman and Chief Executive Officer

       Verizon Communications Inc. 1095 Avenue of the Americas New York, NY 10036    Sweden
    Susan L. Wagner    BlackRock, Inc. - Former Vice Chairman    BlackRock, Inc. 55 East 52nd Street New York, NY 10055    U.S.
    Mark Wilson    Abacai - Co-Chairman and Chief Executive Officer    BlackRock, Inc. 55 East 52nd Street New York, NY 10055    New Zealand


    Annex B

    Transaction in Common Stock

    Since Original Schedule 13D Filing

     

    Legal Entity

       Trade Date    Amount    Trade Price    Buy/Sell

    Aperio Group, LLC

       4/22/2022    86    $4.24    SELL

    Aperio Group, LLC

       4/22/2022    86    $4.22    SELL

    BlackRock Fund Advisors

       5/3/2022    240    $3.77    BUY

    BlackRock Fund Advisors

       5/3/2022    8,245    $3.77    BUY

    BlackRock Fund Advisors

       5/3/2022    510    $3.77    SELL

    BlackRock Fund Advisors

       5/3/2022    1,700    $3.77    SELL

    BlackRock Fund Advisors

       5/3/2022    765    $3.77    SELL

    BlackRock Fund Advisors

       5/3/2022    1,785    $3.77    SELL

    BlackRock Fund Advisors

       5/4/2022    6    $3.75    SELL

    BlackRock Asset Management Ireland Limited

       5/4/2022    102    $3.75    BUY

    BlackRock Fund Advisors

       5/4/2022    850    $3.75    BUY

    BlackRock Fund Advisors

       5/4/2022    170    $3.75    SELL

    BlackRock Fund Advisors

       5/4/2022    5    $3.75    SELL

    BlackRock Fund Advisors

       5/4/2022    1,105    $3.75    SELL

    BlackRock Fund Advisors

       5/4/2022    1,275    $3.75    SELL

    BlackRock Fund Advisors

       5/4/2022    720    $3.75    BUY

    BlackRock Fund Advisors

       5/4/2022    480    $3.75    BUY

    BlackRock Fund Advisors

       5/5/2022    1,360    $3.22    BUY

    BlackRock Fund Advisors

       5/5/2022    255    $3.22    SELL

    BlackRock Asset Management Ireland Limited

       5/5/2022    132    $3.22    BUY

    BlackRock Fund Advisors

       5/5/2022    1,105    $3.22    SELL

    BlackRock Fund Advisors

       5/5/2022    340    $3.22    SELL

    BlackRock Fund Advisors

       5/5/2022    2,125    $3.22    BUY

    BlackRock Fund Advisors

       5/5/2022    1,360    $3.22    SELL

    BlackRock Fund Advisors

       5/5/2022    2,125    $3.22    SELL

    BlackRock Fund Advisors

       5/6/2022    1,785    $4.10    SELL

    BlackRock Fund Advisors

       5/6/2022    595    $4.10    SELL

    BlackRock Fund Advisors

       5/6/2022    1,700    $4.10    SELL

    BlackRock Financial Management, Inc.

       5/6/2022    2,501    $3.83    BUY

    BlackRock Fund Advisors

       5/6/2022    9    $4.10    BUY

    BlackRock Fund Advisors

       5/6/2022    340    $4.10    SELL

    BlackRock Fund Advisors

       5/9/2022    765    $3.90    BUY

    BlackRock Fund Advisors

       5/9/2022    1,700    $3.90    BUY

    BlackRock Fund Advisors

       5/9/2022    2,125    $3.90    BUY

    BlackRock Fund Advisors

       5/9/2022    1,955    $3.90    BUY

    BlackRock Fund Advisors

       5/9/2022    1,020    $3.90    BUY

    BlackRock Fund Advisors

       5/10/2022    1,530    $4.45    BUY

    BlackRock Fund Advisors

       5/10/2022    51    $4.45    SELL

    BlackRock Fund Advisors

       5/10/2022    3,145    $4.45    BUY

    BlackRock Fund Advisors

       5/10/2022    2,295    $4.45    BUY

    BlackRock Fund Advisors

       5/10/2022    2,550    $4.45    BUY


    Legal Entity

       Trade Date    Amount    Trade Price    Buy/Sell

    BlackRock Fund Advisors

       5/11/2022    960    $3.83    BUY

    BlackRock Fund Advisors

       5/11/2022    36    $3.83    BUY

    BlackRock Fund Advisors

       5/11/2022    595    $3.83    SELL

    BlackRock Fund Advisors

       5/11/2022    850    $3.83    SELL

    BlackRock Fund Advisors

       5/11/2022    13    $3.83    BUY

    BlackRock Fund Advisors

       5/11/2022    30    $3.83    BUY

    BlackRock Fund Advisors

       5/11/2022    1,360    $3.83    BUY

    BlackRock Fund Advisors

       5/11/2022    255    $3.83    SELL

    BlackRock Fund Advisors

       5/11/2022    10    $3.83    BUY

    BlackRock Fund Advisors

       5/11/2022    255    $3.83    BUY

    BlackRock Fund Advisors

       5/11/2022    26    $3.83    SELL

    BlackRock Fund Advisors

       5/12/2022    18    $3.88    BUY

    BlackRock Fund Advisors

       5/12/2022    595    $3.88    BUY

    BlackRock Fund Advisors

       5/12/2022    240    $3.88    SELL

    BlackRock Fund Advisors

       5/13/2022    30    $3.55    BUY

    BlackRock Fund Advisors

       5/13/2022    50    $3.55    SELL

    BlackRock Fund Advisors

       5/13/2022    12    $3.55    BUY

    BlackRock Fund Advisors

       5/13/2022    935    $3.55    SELL

    BlackRock Fund Advisors

       5/13/2022    680    $3.55    BUY

    BlackRock Fund Advisors

       5/13/2022    1,955    $3.55    SELL

    BlackRock Fund Advisors

       5/16/2022    7,310    $3.24    BUY

    BlackRock Fund Advisors

       5/16/2022    850    $3.24    SELL

    BlackRock Fund Advisors

       5/16/2022    1,785    $3.24    SELL

    BlackRock Fund Advisors

       5/16/2022    935    $3.24    SELL

    BlackRock Fund Advisors

       5/16/2022    425    $3.24    SELL

    BlackRock Fund Advisors

       5/16/2022    5    $3.24    SELL

    BlackRock Fund Advisors

       5/16/2022    240    $3.24    BUY

    BlackRock Fund Advisors

       5/16/2022    1,020    $3.24    SELL

    BlackRock Fund Advisors

       5/17/2022    1,615    $3.17    SELL

    BlackRock Fund Advisors

       5/17/2022    15    $3.17    BUY

    BlackRock Fund Advisors

       5/17/2022    935    $3.17    SELL

    BlackRock Fund Advisors

       5/18/2022    2,040    $2.81    SELL

    BlackRock Fund Advisors

       5/18/2022    1,020    $2.81    SELL

    BlackRock Fund Advisors

       5/18/2022    1,700    $2.81    SELL

    BlackRock Fund Advisors

       5/18/2022    1,785    $2.81    BUY

    BlackRock Fund Advisors

       5/18/2022    2,210    $2.81    SELL

    BlackRock Fund Advisors

       5/18/2022    720    $2.81    BUY

    BlackRock Fund Advisors

       5/18/2022    1,700    $2.81    SELL

    BlackRock Fund Advisors

       5/18/2022    68    $2.81    BUY

    BlackRock Fund Advisors

       5/18/2022    5    $2.81    BUY

    BlackRock Fund Advisors

       5/18/2022    3,145    $2.81    SELL

    BlackRock Fund Advisors

       5/18/2022    480    $2.81    SELL

    BlackRock Fund Advisors

       5/19/2022    850    $2.67    SELL

    BlackRock Fund Advisors

       5/19/2022    425    $2.67    SELL

    BlackRock Fund Advisors

       5/19/2022    1,500,000    $67.99    BUY

    BlackRock Fund Advisors

       5/19/2022    18    $2.67    SELL


    Legal Entity

       Trade Date    Amount    Trade Price    Buy/Sell

    BlackRock Fund Advisors

       5/19/2022    26    $2.67    SELL

    BlackRock Fund Advisors

       5/19/2022    4,080    $2.67    BUY

    BlackRock Fund Advisors

       5/19/2022    720    $2.67    BUY

    BlackRock Fund Advisors

       5/20/2022    765    $2.30    SELL

    BlackRock Fund Advisors

       5/20/2022    4,420    $2.30    SELL

    BlackRock Fund Advisors

       5/20/2022    170    $2.30    BUY

    BlackRock Fund Advisors

       5/20/2022    2,720    $2.30    SELL

    BlackRock Fund Advisors

       5/20/2022    480    $2.30    SELL

    BlackRock Fund Advisors

       5/20/2022    1,700    $2.30    SELL

    BlackRock Fund Advisors

       5/20/2022    1,020    $2.30    SELL

    BlackRock Fund Advisors

       5/20/2022    595    $2.30    BUY

    BlackRock Fund Advisors

       5/23/2022    720    $2.86    BUY

    BlackRock Fund Advisors

       5/23/2022    2,040    $2.86    BUY

    BlackRock Fund Advisors

       5/23/2022    1,360    $2.86    SELL

    BlackRock Fund Advisors

       5/23/2022    40    $2.86    BUY

    BlackRock Fund Advisors

       5/23/2022    255    $2.86    BUY

    BlackRock Fund Advisors

       5/23/2022    170    $2.86    BUY

    BlackRock Fund Advisors

       5/23/2022    1,190    $2.86    SELL

    BlackRock Fund Advisors

       5/24/2022    4,845    $3.12    BUY

    BlackRock Fund Advisors

       5/24/2022    15    $3.12    BUY

    BlackRock Fund Advisors

       5/24/2022    6    $3.12    SELL

    BlackRock Fund Advisors

       5/24/2022    850    $3.12    BUY

    BlackRock Fund Advisors

       5/24/2022    1,445    $3.12    BUY

    BlackRock Fund Advisors

       5/24/2022    850    $3.12    SELL

    BlackRock Fund Advisors

       5/24/2022    1,530    $3.12    BUY

    Aperio Group, LLC

       5/24/2022    145    $2.97    SELL

    BlackRock Fund Advisors

       5/25/2022    850    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    425    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    480    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    480    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    21    $3.25    BUY

    BlackRock Advisors, LLC

       5/25/2022    10,690    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    480    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    1,200    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    1,190    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    1,020    $3.25    SELL

    BlackRock Fund Advisors

       5/25/2022    425    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    39    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    3,400    $3.25    BUY

    BlackRock Fund Advisors

       5/25/2022    1,190    $3.25    SELL

    BlackRock Fund Advisors

       5/26/2022    1,275    $3.26    BUY

    BlackRock Fund Advisors

       5/26/2022    595    $3.26    BUY

    BlackRock Fund Advisors

       5/26/2022    765    $3.26    SELL

    BlackRock Fund Advisors

       5/26/2022    240    $3.26    BUY

    BlackRock Fund Advisors

       5/26/2022    2,160    $3.26    BUY

    BlackRock Fund Advisors

       5/26/2022    680    $3.26    SELL

    BlackRock Fund Advisors

       5/26/2022    850    $3.26    SELL


    Legal Entity

       Trade Date    Amount    Trade Price    Buy/Sell

    Aperio Group, LLC

       5/26/2022    67    $3.05    SELL

    BlackRock Fund Advisors

       5/27/2022    36    $3.86    SELL

    BlackRock Fund Advisors

       5/27/2022    720    $3.86    BUY

    BlackRock Fund Advisors

       5/27/2022    42    $3.86    BUY

    BlackRock Fund Advisors

       5/27/2022    10    $3.86    BUY

    BlackRock Fund Advisors

       5/27/2022    1,190    $3.86    SELL

    BlackRock Fund Advisors

       5/27/2022    480    $3.86    BUY

    BlackRock Fund Advisors

       5/31/2022    510    $3.64    BUY

    BlackRock Fund Advisors

       5/31/2022    255    $3.64    BUY

    BlackRock Financial Management, Inc.

       5/31/2022    138    $3.64    SELL

    BlackRock Fund Advisors

       5/31/2022    25    $3.64    BUY

    BlackRock Institutional Trust Company, National Association

       5/31/2022    7,256    $3.64    SELL

    BlackRock Asset Management Ireland Limited

       5/31/2022    11,229    $3.64    SELL

    BlackRock Financial Management, Inc.

       5/31/2022    5,539    $3.64    SELL

    BlackRock Institutional Trust Company, National Association

       5/31/2022    534    $3.64    SELL

    BlackRock Fund Advisors

       5/31/2022    425    $3.64    BUY

    BlackRock Fund Advisors

       5/31/2022    510    $3.64    SELL

    BlackRock Institutional Trust Company, National Association

       5/31/2022    574    $3.64    SELL

    BlackRock Financial Management, Inc.

       5/31/2022    2,055    $3.64    SELL

    BlackRock Institutional Trust Company, National Association

       5/31/2022    191    $3.64    SELL

    BlackRock Fund Advisors

       5/31/2022    21    $3.64    BUY

    BlackRock Fund Advisors

       5/31/2022    935    $3.64    BUY

    BlackRock Institutional Trust Company, National Association

       5/31/2022    52    $3.64    SELL

    BlackRock Fund Advisors

       5/31/2022    240    $3.64    SELL

    BlackRock Fund Advisors

       5/31/2022    18    $3.64    BUY

    BlackRock Asset Management Ireland Limited

       5/31/2022    5,503    $3.64    SELL

    BlackRock Financial Management, Inc.

       5/31/2022    9,819    $3.64    SELL

    BlackRock Fund Advisors

       5/31/2022    765    $3.64    SELL

    BlackRock Fund Advisors

       5/31/2022    30    $3.64    BUY

    BlackRock Investment Management (UK) Limited

       5/31/2022    2,516    $3.64    SELL

    BlackRock Fund Advisors

       5/31/2022    11,432    $3.64    SELL

    BlackRock Asset Management Schweiz AG

       5/31/2022    2,853    $3.64    SELL

    BlackRock Fund Managers Ltd

       5/31/2022    2,877    $3.64    SELL

    BlackRock Institutional Trust Company, National Association

       5/31/2022    118    $3.64    SELL

    BlackRock Investment Management (Australia) Limited

       5/31/2022    131    $3.64    SELL

    BlackRock Investment Management (UK) Limited

       5/31/2022    5,954    $3.64    SELL

    BlackRock Fund Advisors

       6/1/2022    510    $3.05    SELL

    BlackRock Fund Advisors

       6/1/2022    1,360    $3.05    SELL

    BlackRock Fund Advisors

       6/1/2022    510    $3.05    SELL

    BlackRock Fund Advisors

       6/1/2022    680    $3.05    SELL

    BlackRock Fund Advisors

       6/1/2022    4,675    $3.05    BUY

    BlackRock Fund Advisors

       6/1/2022    480    $3.05    BUY

    BlackRock Fund Advisors

       6/2/2022    680    $3.11    SELL

    BlackRock Fund Advisors

       6/2/2022    1,020    $3.11    SELL

    BlackRock Fund Advisors

       6/2/2022    425    $3.11    SELL

    BlackRock Fund Advisors

       6/2/2022    680    $3.11    BUY

    BlackRock Fund Advisors

       6/3/2022    935    $3.32    SELL


    Legal Entity

       Trade Date    Amount    Trade Price    Buy/Sell

    BlackRock Fund Advisors

       6/3/2022    1,445    $3.32    SELL

    BlackRock Fund Advisors

       6/3/2022    680    $3.32    SELL

    BlackRock Fund Advisors

       6/3/2022    510    $3.32    SELL

    BlackRock Fund Advisors

       6/3/2022    960    $3.32    BUY

    BlackRock Advisors, LLC

       6/3/2022    2,179    $3.32    SELL

    BlackRock Fund Advisors

       6/6/2022    765    $3.47    SELL

    BlackRock Fund Advisors

       6/6/2022    960    $3.47    SELL

    BlackRock Fund Advisors

       6/6/2022    720    $3.47    BUY

    BlackRock Fund Advisors

       6/6/2022    935    $3.47    SELL

    BlackRock Fund Advisors

       6/6/2022    1,360    $3.47    SELL

    BlackRock Fund Advisors

       6/6/2022    720    $3.47    BUY

    BlackRock Fund Advisors

       6/6/2022    1,445    $3.47    BUY

    BlackRock Fund Advisors

       6/6/2022    1,360    $3.47    SELL

    BlackRock Fund Advisors

       6/7/2022    1,700    $3.80    BUY

    BlackRock Fund Advisors

       6/7/2022    1,105    $3.80    SELL

    BlackRock Fund Advisors

       6/7/2022    1,020    $3.80    SELL

    BlackRock Fund Advisors

       6/7/2022    240    $3.80    SELL

    BlackRock Fund Advisors

       6/7/2022    1,870    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    1,190    $3.80    BUY

    BlackRock Fund Advisors

       6/8/2022    10    $3.80    BUY

    BlackRock Fund Advisors

       6/8/2022    15    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    72    $3.80    BUY

    BlackRock Fund Advisors

       6/8/2022    255    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    3,400    $3.80    BUY

    BlackRock Fund Advisors

       6/8/2022    935    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    480    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    425    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    240    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    170    $3.80    BUY

    BlackRock Fund Advisors

       6/8/2022    18    $3.80    BUY

    BlackRock Fund Advisors

       6/8/2022    240    $3.80    BUY

    BlackRock Fund Advisors

       6/8/2022    935    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    595    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    255    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    2,550    $3.80    BUY

    BlackRock Fund Advisors

       6/8/2022    1,530    $3.80    SELL

    BlackRock Fund Advisors

       6/8/2022    680    $3.80    BUY

    BlackRock Fund Advisors

       6/9/2022    680    $3.86    SELL

    BlackRock Fund Advisors

       6/9/2022    25    $3.86    SELL

    BlackRock Fund Advisors

       6/9/2022    2,125    $3.86    BUY

    BlackRock Fund Advisors

       6/9/2022    935    $3.86    BUY

    BlackRock Fund Advisors

       6/9/2022    480    $3.86    SELL

    BlackRock Fund Advisors

       6/9/2022    1,360    $3.86    BUY

    BlackRock Fund Advisors

       6/9/2022    2,550    $3.86    BUY

    BlackRock Fund Advisors

       6/9/2022    1,020    $3.86    SELL

    BlackRock Fund Advisors

       6/9/2022    1,700    $3.86    BUY

    BlackRock Fund Advisors

       6/10/2022    18    $3.60    BUY


    Legal Entity

       Trade Date    Amount    Trade Price    Buy/Sell

    BlackRock Fund Advisors

       6/10/2022    680    $3.60    SELL

    BlackRock Fund Advisors

       6/10/2022    20    $3.60    SELL

    BlackRock Fund Advisors

       6/13/2022    1,700    $3.30    BUY

    BlackRock Fund Advisors

       6/13/2022    4,080    $3.30    BUY

    BlackRock Fund Advisors

       6/13/2022    84    $3.30    BUY

    BlackRock Fund Advisors

       6/13/2022    1,530    $3.30    SELL

    BlackRock Fund Advisors

       6/13/2022    4,250    $3.30    BUY

    BlackRock Fund Advisors

       6/13/2022    34    $3.30    BUY

    BlackRock Fund Advisors

       6/13/2022    1,870    $3.30    BUY

    BlackRock Institutional Trust Company, National Association

       6/13/2022    1,389    $3.24    BUY

    Aperio Group, LLC

       6/14/2022    289    $3.04    SELL

    BlackRock Fund Advisors

       6/14/2022    3,400    $3.01    BUY

    BlackRock Fund Advisors

       6/14/2022    1,445    $3.01    BUY

    BlackRock Fund Advisors

       6/14/2022    51    $3.01    BUY

    BlackRock Fund Advisors

       6/14/2022    1,105    $3.01    BUY

    BlackRock Fund Advisors

       6/14/2022    765    $3.01    BUY

    BlackRock Fund Advisors

       6/14/2022    240    $3.01    BUY

    BlackRock Fund Advisors

       6/14/2022    2,040    $3.01    BUY

    Aperio Group, LLC

       6/15/2022    198    $3.12    SELL

    BlackRock Fund Advisors

       6/15/2022    30    $3.07    BUY

    BlackRock Fund Advisors

       6/15/2022    1,700    $3.07    SELL

    BlackRock Fund Advisors

       6/15/2022    1,700    $3.07    SELL

    BlackRock Fund Advisors

       6/15/2022    170    $3.07    BUY

    BlackRock Fund Advisors

       6/15/2022    1,105    $3.07    BUY

    BlackRock Fund Advisors

       6/15/2022    480    $3.07    BUY

    BlackRock Fund Advisors

       6/15/2022    1,190    $3.07    BUY

    BlackRock Fund Advisors

       6/15/2022    18    $3.07    BUY

    BlackRock Fund Advisors

       6/16/2022    1,530    $2.87    BUY

    BlackRock Fund Advisors

       6/16/2022    2,210    $2.87    BUY

    BlackRock Fund Advisors

       6/16/2022    2,125    $2.87    BUY

    BlackRock Fund Advisors

       6/16/2022    935    $2.87    BUY

    BlackRock Fund Advisors

       6/16/2022    680    $2.87    SELL

    BlackRock Fund Advisors

       6/16/2022    3,655    $2.87    BUY

    BlackRock Fund Advisors

       6/16/2022    1,360    $2.87    SELL

    BlackRock Fund Advisors

       6/16/2022    3,060    $2.87    BUY
    Get the next $TRHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TRHC

    DatePrice TargetRatingAnalyst
    5/10/2023$7.00 → $10.00Market Perform → Outperform
    SVB Securities
    3/2/2022$30.00 → $15.00Buy
    Benchmark
    2/28/2022$23.00 → $11.00Market Perform
    SVB Leerink
    2/1/2022$24.00 → $11.00Outperform → Neutral
    Robert W. Baird
    2/1/2022$24.00 → $11.00Outperform → Neutral
    Baird
    12/2/2021$13.00Hold
    Jefferies
    11/8/2021$70.00 → $23.00Outperform
    RBC Capital
    11/8/2021$40.00 → $23.00Market Perform
    SVB Leerink
    More analyst ratings

    $TRHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Tabula Rasa HealthCare Provides Corporate Updates

      Appoints Brian Adams as President and Chief Executive Officer and a Member of the Board of Directors, Effective Immediately Appoints Richard W. Rew II as Chief Legal Officer and Corporate Secretary Announces Preliminary Unaudited First Quarter 2023 Revenue Exceeding Guidance MOORESTOWN, N.J., April 13, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of Brian Adams as President and Chief Executive Officer. Mr. Adams, who was serving as TRHC's interim Chief Executive Officer since September 2022 and previously served as the Company's Co-Pre

      4/13/23 4:05:00 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa HealthCare Names April Gill Chief Commercial Officer

      MOORESTOWN, N.J., Nov. 1, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced the appointment of April D. Gill as Chief Commercial Officer. Ms. Gill has more than 20 years of experience in healthcare with a proven track record exceeding client satisfaction, sales, and profitability goals. In this newly created role, Ms. Gill will oversee development and execution of TRHC's commercialization with broad responsibility for strategy, product, marketing, communication

      11/1/22 8:30:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa HealthCare Announces Leadership Transition

      Drs. Calvin H. Knowlton and Orsula V. Knowlton to retire from the Company Co-President Brian Adams Named Interim CEO Director Michael Purcell Named Independent Board Chairman MOORESTOWN, N.J., Sept. 14, 2022 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ:TRHC), a leading healthcare technology company advancing the safe use of medications, today announced that co-founders Dr. Calvin H. Knowlton, BScPharm, MDiv, PhD, ScD (hon), Chief Executive Officer and Board Chairman, and Dr. Orsula V. Knowlton, PharmD, MBA, Co-President and Chief Marketing and New Business Development Officer, will retire from TRHC and step down as members of the Board of Directors, effective immediately. Dir

      9/14/22 8:00:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    Financials

    Live finance-specific insights

    See more
    • Tabula Rasa HealthCare Reports Second Quarter 2023 Financial Results

      Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million

      8/7/23 7:02:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa HealthCare Schedules Second Quarter 2023 Earnings Conference Call

      MOORESTOWN, N.J., July 25, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), will hold a conference call and webcast to discuss its second quarter 2023 financial results Tuesday, August 8, 2023 at 8:30 a.m. EDT. The Company's financial results for the second quarter 2023 ended June 30, 2023, will be released after the close of the market Monday, August 7, 2023. Those interested in participating via webcast in listen-only mode can access the event here. For participants who would like to participate via telephone, please register here to receive the dial-in numbe

      7/25/23 4:30:00 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa HealthCare Reports First Quarter 2023 Financial Results

      First Quarter Results Show Benefits of Consistent Execution on Financial and Strategic Objectives First Quarter Revenue Growth of 32% Compared to First Quarter 2022 Raises Full Year 2023 Revenue and Adjusted EBITDA Guidance MOORESTOWN, N.J., May 8, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare technology company advancing the safe use of medications, today reported financial results for the first quarter ended March 31, 2023. Highlights from the first quarter ended March 31, 2023, include: First quarter revenu

      5/8/23 4:30:00 PM ET
      $TRHC
      Business Services
      Consumer Discretionary

    $TRHC
    SEC Filings

    See more

    $TRHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TRHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $TRHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TRHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form EFFECT filed by Tabula Rasa HealthCare Inc.

      EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)

      11/17/23 12:15:07 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Tabula Rasa HealthCare Inc.

      EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)

      11/17/23 12:15:26 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form EFFECT filed by Tabula Rasa HealthCare Inc.

      EFFECT - Tabula Rasa HealthCare, Inc. (0001651561) (Filer)

      11/17/23 12:15:13 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Lifshitz Law PLLC Announces Investigations of VRTV, FRGI, TRHC, and SOVO

      NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Veritiv Corporation (NYSE:VRTV) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of VRTV to an affiliate of Clayton, Dubilier & Rice, LCC for $170.00 per share in cash for each share of VRTV common stock owned. If you are a VRTV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Fiesta Restaurant Group, Inc. (NASDAQ:FRGI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary dutie

      8/12/23 8:17:00 PM ET
      $FRGI
      $SOVO
      $TRHC
      $VRTV
      Restaurants
      Consumer Discretionary
      Packaged Foods
      Consumer Staples
    • Tabula Rasa HealthCare Reports Second Quarter 2023 Financial Results

      Continued Strong Organic Revenue Growth of 24% Second Quarter Adjusted EBITDA of $6.3 Million Increased More Than 3x Compared to Second Quarter 2022 MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® (NASDAQ:TRHC) ("TRHC" or the "Company"), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today reported financial results for the second quarter ended June 30, 2023. Highlights from the second quarter ended June 30, 2023 include: Second quarter revenue from continuing operations of $90.0 million

      8/7/23 7:02:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa and ExactCare to Combine to Create a Leading, Independent Pharmacy Care Management Company That Services Patients with the Most Complex Needs

      $10.50 Per Share All-Cash Transaction Represents a Significant Premium for Tabula Rasa Stockholders Combination of Two Highly Complementary Companies to Benefit Patients, Providers and Payers with First of its Kind Risk Management Platform in Pharmacy Care Expands the Reach of Tabula Rasa's MedWise Technology Platform to Multiple Provider and Payer Markets MOORESTOWN, N.J., Aug. 7, 2023 /PRNewswire/ -- Tabula Rasa HealthCare, Inc.® ("TRHC," "Tabula Rasa" or the "Company") (NASDAQ:TRHC), a leading healthcare company advancing personalized, comprehensive care for value-based care organizations, today announced it has entered into a definitive agreement (the "Agreement") to be acquired by Nauti

      8/7/23 7:00:00 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Mitchell Ronald Paul returned 79,332 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)

      11/14/23 9:09:01 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Purcell Michael J. returned 139,322 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)

      11/14/23 9:02:19 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Schwartz Jonathan David returned 78,388 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Tabula Rasa HealthCare, Inc. (0001651561) (Issuer)

      11/14/23 8:59:36 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Tabula Rasa HealthCare upgraded by SVB Securities with a new price target

      SVB Securities upgraded Tabula Rasa HealthCare from Market Perform to Outperform and set a new price target of $10.00 from $7.00 previously

      5/10/23 6:30:40 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • Benchmark reiterated coverage on Tabula Rasa HealthCare with a new price target

      Benchmark reiterated coverage of Tabula Rasa HealthCare with a rating of Buy and set a new price target of $15.00 from $30.00 previously

      3/2/22 7:40:57 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SVB Leerink reiterated coverage on Tabula Rasa HealthCare with a new price target

      SVB Leerink reiterated coverage of Tabula Rasa HealthCare with a rating of Market Perform and set a new price target of $11.00 from $23.00 previously

      2/28/22 4:58:06 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Tabula Rasa HealthCare Inc. (Amendment)

      SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)

      8/8/23 4:01:33 PM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Tabula Rasa HealthCare Inc. (Amendment)

      SC 13G/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)

      2/9/23 11:35:13 AM ET
      $TRHC
      Business Services
      Consumer Discretionary
    • SEC Form SC 13D/A filed by Tabula Rasa HealthCare Inc. (Amendment)

      SC 13D/A - Tabula Rasa HealthCare, Inc. (0001651561) (Subject)

      9/14/22 3:21:21 PM ET
      $TRHC
      Business Services
      Consumer Discretionary